(P100) Radiation Therapy Is Associated With Improved Survival In Patients With Localized Pancreatic Cancer S/P Whipple Procedure Without Increased Morbidity: Results of a Study from the Surveillance, Epidemiology, and End Results (SEER) Registry Data

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

For the current study, we evaluated the effect of adjuvant RT on survival as well as treatment-related toxicity in patients with localized pancreatic cancer who underwent Whipple procedure (pancreaticoduodenectomy).

Weisi Yan, MD, Julia Manzerova, MD, PhD, Jason C. Ye, MD, Paul Christos, DrPH, MS, Dattatreyudu Nori, MD, MBBS, Kun-San C. Chao, MD, Akkamma Ravi, MD, MBBS; New York Hospital Queens; New York Presbyterian Hospital; Weill Cornell Medical College

Background: Patients with localized pancreatic cancer tend to receive chemotherapy after surgery. However, the role of radiation therapy (RT) in resectable pancreatic cancer is still debated. For the current study, we evaluated the effect of adjuvant RT on survival as well as treatment-related toxicity in patients with localized pancreatic cancer who underwent Whipple procedure (pancreaticoduodenectomy).

Methods: The analysis included 3,721 patients reported to the Surveillance, Epidemiology, and End Results (SEER) registry of the National Cancer Institute from 2003 to 2010 who had localized pancreatic cancer and underwent a cancer-directed Whipple procedure (pancreaticoduodenectomy). Cause-specific survival (CSS) was evaluated by Kaplan-Meier survival analysis, and the log-rank test was used to compare CSS between treatment categories of interest. Multivariable Cox regression model analysis was used to elucidate the factors that contribute to pancreatic cancer death. Adjusted hazard ratios (AHRs) and 95% confidence intervals (95% CIs) were calculated for risk of pancreatic cancer-related death. Deaths due to RT were also studied.

Results: Of the 3,721 patients, 1,520 (40.8%) received RT. Median follow-up time (based on survivors) was 17 months (range: 0.10–83.0 mo). CSS improved significantly in patients who received RT, with a median survival of 21.0 months (95% CI, 19.8–22.2 mo) compared with 17 months (95% CI, 15.8–18.2 mo) for patients who did not receive RT (P < .0001). On multivariable analysis, age > 65 years, T-stage, N-stage, and grade were associated with increased risk of pancreatic-specific death (P < .05 for all factors). Out of 1,520 cases, 4 (0.2%) patients died of radiation treatment effects; out of a total of 2,201 cases, 6 (0.2%) patients died of surgery and/or chemotherapy treatment effects.

Conclusions: Adjuvant RT following Whipple procedure was associated with improved CSS compared with cancer-directed surgery alone without radiation in patients with localized pancreatic cancer. Old age, white race, higher T- and N-stage, and grade were associated with worse outcome. Morbidity was not increased with adjuvant RT.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Related Content